Glaukos (GKOS) Competitors

Zimmer Biomet (NYSE:ZBH) and Glaukos (NYSE:GKOS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

Do insiders & institutionals hold more shares of ZBH or GKOS?

88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 99.0% of Glaukos shares are owned by institutional investors. 1.0% of Zimmer Biomet shares are owned by insiders. Comparatively, 6.4% of Glaukos shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Do analysts prefer ZBH or GKOS?

Zimmer Biomet presently has a consensus price target of $126.00, suggesting a potential upside of 20.22%. Glaukos has a consensus price target of $129.82, suggesting a potential upside of 0.42%. Given Zimmer Biomet's higher probable upside, research analysts clearly believe Zimmer Biomet is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	2 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.21
Glaukos	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Does the MarketBeat Community believe in ZBH or GKOS?

Zimmer Biomet received 459 more outperform votes than Glaukos when rated by MarketBeat users. Likewise, 67.57% of users gave Zimmer Biomet an outperform vote while only 64.54% of users gave Glaukos an outperform vote.

Company	Underperform	Outperform
Zimmer Biomet	Outperform Votes 894 67.57%	Underperform Votes 429 32.43%
Glaukos	Outperform Votes 435 64.54%	Underperform Votes 239 35.46%

Is ZBH or GKOS more profitable?

Zimmer Biomet has a net margin of 13.25% compared to Glaukos' net margin of -47.39%. Zimmer Biomet's return on equity of 12.86% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	13.25%	12.86%	7.56%
Glaukos	-47.39%	-22.51%	-12.36%

Which has higher earnings and valuation, ZBH or GKOS?

Zimmer Biomet has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$7.39B	2.89	$1.02B	$4.62	22.69
Glaukos	$341.73M	19.06	-$134.66M	-$2.88	-44.89

Which has more risk & volatility, ZBH or GKOS?

Zimmer Biomet has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Glaukos has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500.

Does the media refer more to ZBH or GKOS?

In the previous week, Zimmer Biomet had 22 more articles in the media than Glaukos. MarketBeat recorded 30 mentions for Zimmer Biomet and 8 mentions for Glaukos. Glaukos' average media sentiment score of 0.44 beat Zimmer Biomet's score of 0.20 indicating that Glaukos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	9 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Glaukos	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Zimmer Biomet beats Glaukos on 11 of the 18 factors compared between the two stocks.